A dominant interfering Myb mutant causes apoptosis in T cells

被引:162
作者
Taylor, D [1 ]
Badiani, P [1 ]
Weston, K [1 ]
机构
[1] INST CANC RES, CRC, CTR CELL & MOL BIOL, LONDON SW3 6JB, ENGLAND
关键词
Myb; apoptosis; bcl-2; T cells; transcriptional control;
D O I
10.1101/gad.10.21.2732
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The c-Myb transcription factor is required for the production of most hemopoietic lineages, but information is sparse about its mode of action and the key genes it regulates. We have made an inducible dominant interfering Myb protein, by creating a chimera comprising the DNA binding domain of c-Myb, the Drosophila Engrailed repressor domain, and a modified estrogen receptor hormone binding domain. When expressed in the murine thymoma cell line EL4, activation of this mutant results in a significant proportion of the cell population undergoing apoptosis, as assessed by nuclear breakdown and DNA fragmentation, but has no apparent effect on cell-cycle progression. The apoptotic phenotype is mirrored during thymopoiesis in transgenic mice expressing dominant interfering Myb mutants; their T cells are fragile both in vivo and in vitro. Induction of the Myb dominant interfering mutant in EL4 cells correlates with down-regulation of bcl-2, but does not affect transcription of other bcl-2 family members; conversely, overexpression of bcl-2 in the transgenic mouse model rescues thymocytes from death. Analysis of the bcl-2 promoter by run-on transcription, bandshifting, and transient expression assays shows that it is a direct target of Myb. These data suggest a new and important role for Myb proteins as regulators of cell survival during hemopoiesis.
引用
收藏
页码:2732 / 2744
页数:13
相关论文
共 62 条
[1]   ABERRANT EXPRESSION OF AN AMPLIFIED C-MYB ONCOGENE IN 2 CELL-LINES FROM A COLON-CARCINOMA [J].
ALITALO, K ;
WINQVIST, R ;
LIN, CC ;
DELACHAPELLE, A ;
SCHWAB, M ;
BISHOP, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (14) :4534-4538
[2]  
[Anonymous], 1991, CURRENT PROTOCOLS IM
[3]  
ARSURA M, 1992, BLOOD, V79, P2708
[4]   DOMINANT INTERFERING ALLELES DEFINE A ROLE FOR C-MYB IN T-CELL DEVELOPMENT [J].
BADIANI, P ;
CORBELLA, P ;
KIOUSSIS, D ;
MARVEL, J ;
WESTON, K .
GENES & DEVELOPMENT, 1994, 8 (07) :770-782
[5]   RELATIONSHIP BETWEEN THE C-MYB LOCUS AND THE 6Q CHROMOSOMAL ABERRATION IN LEUKEMIAS AND LYMPHOMAS [J].
BARLETTA, C ;
PELICCI, PG ;
KENYON, LC ;
SMITH, SD ;
DALLAFAVERA, R .
SCIENCE, 1987, 235 (4792) :1064-1067
[6]  
BIES J, 1995, CANCER RES, V55, P501
[7]  
Bies J, 1996, ONCOGENE, V12, P355
[8]  
BLOOMFIELD CD, 1983, CANCER RES, V43, P2975
[9]   THE ANTIPROLIFERATIVE ACTIVITY OF C-MYB AND C-MYC ANTISENSE OLIGONUCLEOTIDES IN SMOOTH-MUSCLE CELLS IS CAUSED BY A NONANTISENSE MECHANISM [J].
BURGESS, TL ;
FISHER, EF ;
ROSS, SL ;
BREADY, JV ;
QIAN, YX ;
BAYEWITCH, LA ;
COHEN, AM ;
HERRERA, CJ ;
HU, SSF ;
KRAMER, TB ;
LOTT, FD ;
MARTIN, FH ;
PIERCE, GF ;
SIMONET, L ;
FARRELL, CL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (09) :4051-4055
[10]  
CALABRETTA B, 1991, CANCER RES, V51, P4505